3.
不同临床特征与无进展生存期的关系
Relationship between different clinical features with PFS
| Category | mPFS (mon) | 95%CI | P | |
| mPFS: median progression free survival; CI: confidence interval. | ||||
| Age (yr) | < 65 | 7.1 | 4.365-9.835 | 0.962 |
| ≥65 | 7.0 | 3.514-10.486 | ||
| Gender | Male | 7.1 | 4.761-9.439 | 0.725 |
| Female | 4.5 | 1.499-7.501 | ||
| Smoking status | Smoker | 7.1 | 4.726-9.474 | 0.834 |
| Non-smoker | 4.5 | 1.530-7.470 | ||
| Performance status (ECOG) | 0-1 | 7.6 | 5.101-10.099 | 0.101 |
| 2 | 5.1 | 0.000-12.622 | ||
| Pathological type | Adenocarcinoma | 7.1 | 3.465-10.735 | 0.563 |
| Squamous cell carcinoma | 6.8 | 4.875-8.725 | ||
| Tumor size (cm) | < 5 | 7.6 | 6.221-8.979 | 0.088 |
| ≥5 | 4.6 | 1.486-7.714 | ||
| TNM stage | Ⅲb | 8.0 | 0.552-15.448 | 0.223 |
| Ⅳ | 6.8 | 4.469-9.131 | ||
| Immunotherapy protocols | Monotherapy | 8.0 | 4.304-11.696 | 0.502 |
| Combination therapy | 6.8 | 4.597-9.003 | ||
| Immunotherapy lines | First-line therapy | 7.0 | 0.000-14.998 | 0.340 |
| Subsequent therapy | 7.1 | 3.093-11.107 | ||